434 related articles for article (PubMed ID: 33781929)
1. Timing of Complete Polypoidal Regression after Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy.
Chaikitmongkol V; Upaphong P; Patikulsila D; Jirarattanasopa P; Choovuthayakorn J; Watanachai N; Kunavisarut P; Ratanasukon M; Bhurayanontachai P; Ingviya T; Bressler SB; Bressler NM
Ophthalmol Retina; 2022 Jan; 6(1):21-28. PubMed ID: 33781929
[TBL] [Abstract][Full Text] [Related]
2. Aflibercept Treatment in Polypoidal Choroidal Vasculopathy: Results of a Prospective Study in a Caucasian Population.
Wolff B; Vasseur V; Cahuzac A; Coscas F; Castelnovo L; Favard C; Michel G; Français C; Salomon L; Mauget-Faÿsse M
Ophthalmologica; 2018; 240(4):208-212. PubMed ID: 29804123
[TBL] [Abstract][Full Text] [Related]
3. Initial treatment for polypoidal choroidal vasculopathy: Ranibizumab combined with photodynamic therapy or fixed-dosing aflibercept monotherapy.
Yoneda A; Wakiyama H; Kurihara J; Kitaoka T
Eur J Ophthalmol; 2020 Nov; 30(6):1473-1479. PubMed ID: 31476891
[TBL] [Abstract][Full Text] [Related]
4. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
Matsumiya W; Honda S; Otsuka K; Miki A; Nagai T; Imai H; Kusuhara S; Nakamura M
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):541-548. PubMed ID: 27687988
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.
Lim TH; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Lee WK; Cheung CMG; Ngah NF; Patalauskaite R; Margaron P; Koh A;
JAMA Ophthalmol; 2020 Sep; 138(9):935-942. PubMed ID: 32672800
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study.
Lee JE; Shin JP; Kim HW; Chang W; Kim YC; Lee SJ; Chung IY; Lee JE;
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):493-502. PubMed ID: 27628062
[TBL] [Abstract][Full Text] [Related]
8. Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians.
Fenner BJ; Ting DSW; Tan ACS; Teo K; Chan CM; Mathur R; Yeo IYS; Wong TY; Wong EYM; Cheung CMG
Ophthalmol Retina; 2020 Apr; 4(4):403-414. PubMed ID: 31953109
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: Two-Year Results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study.
Wong TY; Ogura Y; Lee WK; Iida T; Chen SJ; Mitchell P; Gemmy Cheung CM; Zhang Z; Leal S; Ishibashi T;
Am J Ophthalmol; 2019 Aug; 204():80-89. PubMed ID: 30849345
[TBL] [Abstract][Full Text] [Related]
10. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.
Morimoto M; Matsumoto H; Mimura K; Akiyama H
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1891-1897. PubMed ID: 28669041
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
Ogasawara M; Koizumi H; Yamamoto A; Itagaki K; Saito M; Maruko I; Okada AA; Iida T; Sekiryu T
Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
[TBL] [Abstract][Full Text] [Related]
12. Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports.
Iesato Y; Tanaka M; Murata M; Kitahara J; Hirano T; Kurenuma T; Yoshida N; Murata T
BMC Ophthalmol; 2018 Nov; 18(1):284. PubMed ID: 30390650
[TBL] [Abstract][Full Text] [Related]
13. OPTICAL COHERENCE TOMOGRAPHY FEATURES OF POLYPOIDAL LESION CLOSURE IN POLYPOIDAL CHOROIDAL VASCULOPATHY TREATED WITH AFLIBERCEPT.
Tan ACS; Jordan-Yu JM; Vyas CH; Gan ATL; Teo KYC; Chan CM; Mathur R; Wong TY; Chakravarthy U; Cheung GCM
Retina; 2022 Jan; 42(1):114-122. PubMed ID: 34412103
[TBL] [Abstract][Full Text] [Related]
14. Optic disk melanocytoma associated with polypoidal choroidal vasculopathy lesions, after combination treatment of photodynamic therapy and intavitreal aflibercept (Eylea), a case report.
Rouvas A; Gouliopoulos NS; Moschos MM; Theodossiadis P
BMC Ophthalmol; 2018 Oct; 18(1):267. PubMed ID: 30309335
[TBL] [Abstract][Full Text] [Related]
15. Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy.
Jeong S; Sagong M
Br J Ophthalmol; 2017 Jun; 101(6):758-763. PubMed ID: 27597740
[TBL] [Abstract][Full Text] [Related]
16. CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Sakurada Y; Sugiyama A; Tanabe N; Kikushima W; Kume A; Iijima H
Retina; 2017 Oct; 37(10):1866-1872. PubMed ID: 28002268
[TBL] [Abstract][Full Text] [Related]
17. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
Koh A; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Feller C; Margaron P; Lim TH; Lee WK;
JAMA Ophthalmol; 2017 Nov; 135(11):1206-1213. PubMed ID: 28983556
[TBL] [Abstract][Full Text] [Related]
19. Association between the arm-to-choroidal circulation time and clinical profile in patients with polypoidal choroidal vasculopathy.
Mukai R; Itagaki K; Honjyo J; Tanaka K; Norikawa K; Sekiryu T
Jpn J Ophthalmol; 2024 May; 68(3):211-215. PubMed ID: 38609716
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
Kim JH; Kim CG; Lee DW; Yoo SJ; Lew YJ; Cho HJ; Kim JY; Lee SH; Kim JW
Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):107-116. PubMed ID: 31741044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
